The long-term results of levodopa therapy in Parkinsonian patients is described. Between January 1969 and December 1972, dopaminergic therapy was started in 186 patients with Parkinson's disease. Their progress after six months, five years and in the autumn of 1980, was assessed. The initial benefit in the majority of patients was followed by a gradual loss of efficacy in most patients with increasing side effects of central-mediated type. We suggest that it may be wise to delay the onset of levodopa therapy until progress of the disease makes treatment imperative.
MawdsleyC. Treatment of parkinsonism with levodopa. Br Med J1970; 1:331–337.
2.
MawdsleyCWilliamsIRPullarIADavidsonDLKinlochHNC. Treatment of Parkinsonism with amantadine and levodopa. Clin Pharmacol Ther1972; 13:575–583.
3.
MarsdenCDSchnachterM. Assessment of extra pyramidal disorders. Br J Clin Pharmac1981; 11:129–151.
4.
MarkhamCHTreciokasLJDiamondSG. Parkinson's disease and levodopa: A five-year follow-up and review. West J Med1974; 121:188–206.
5.
BarbeauA. Six years of high-level levodopa therapy in severely akinetic Parkinsonian patients. Arch Neurol1976; 33:333–338.
6.
MarsdenCDParkesJD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet1977; 1:345–349.
7.
DelaneyPFermaglichJ. Parkinsonism and levodopa: A five year experience. J Clin Pharmacol1976; 16:652–659.
8.
ShawKMLeesAJSterneGM. The impact of treatment with levodopa on Parkinson's disease. Q J Med1980; 49:283–293.
9.
CastaignePRondotPRibadean-DumasJLCardonP. Long-term treatment of Parkinson's disease with L/dopa alone and in combination with a decarboxylase inhibitor. In BirkmayerWHornykiewiczO, Ed. Advances in Parkinsonism. Basle: Roche Scientific Press: 462–468.
10.
HoehnMMYahrMD. Parkinsonism: Onset, progression and mortality. Neurology1967; 17:427–442.
11.
LesserRP. Analysis of the clinical problems in Parkinsonism and the complications of long-termlevodopa therapy. Neurology1979; 29:1253–1260.
12.
BarbeauA. High level levodopa therapy in severely akinetic Parkinsonian patients: Twelve years later. In RinneUKKlingerMStammG, Ed. Parkinson's disease. Amsterdam: Elsevier/North Holland Biomedical Press; 229–239.
